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ABSTRACT
Introduction The use of immune- checkpoint inhibitors 
has drastically improved the management of patients 
with non- small cell lung cancer (NSCLC), but innate 
and acquired resistances are hurdles needed to be 
solved. Immunomodulatory drugs that can reinvigorate 
the immune cytotoxic activity, in combination with 
antiprogrammed cell death 1 (PD-1) antibody, are a great 
promise to overcome resistance. We evaluated the impact 
of the SRC family kinases (SFKs) on NSCLC prognosis, 
and the immunomodulatory effect of the SFK inhibitor 
dasatinib, in combination with anti- PD-1, in clinically 
relevant mouse models of NSCLC.
Methods A cohort of patients from University Clinic of 
Navarra (n=116) was used to study immune infiltrates 
by multiplex immunofluorescence (mIF) and YES1 protein 
expression in tumor samples. Publicly available resources 
(TCGA, Km Plotter, and CIBERSORT) were used to study 
patient’s survival based on expression of SFKs and tumor 
infiltrates. Syngeneic NSCLC mouse models 393P and 
UNSCC680AJ were used for in vivo drug testing.
Results Among the SFK members, YES1 expression 
showed the highest association with poor prognosis. 
Patients with high YES1 tumor levels also showed high 
infiltration of CD4+/FOXP3+ cells (regulatory T cells 
(Tregs)), suggesting an immunosuppressive phenotype. 
After testing for YES1 expression in a panel of murine 
cell lines, 393P and UNSCC680AJ were selected for in 
vivo studies. In the 393P model, dasatinib+anti- PD-1 
treatment resulted in synergistic activity, with 87% tumor 
regressions and development of immunological memory 
that impeded tumor growth when mice were rechallenged. 
In vivo depletion experiments further showed that 
CD8+ and CD4+ cells are necessary for the therapeutic 
effect of the combination. The antitumor activity was 
accompanied by a very significant decrease in the number 
of Tregs, which was validated by mIF in tumor sections. 
In the UNSCC680AJ model, the antitumor effects of 
dasatinib+anti- PD-1 were milder but similar to the 393P 
model. In in vitro assays, we demonstrated that dasatinib 
blocks proliferation and transforming growth factor beta- 
driven conversion of effector CD4+ cells into Tregs through 
targeting of phospholymphocyte- specific protein tyrosine 
kinase and downstream effectors pSTAT5 and pSMAD3.
Conclusions YES1 protein expression is associated 
with increased numbers of Tregs in patients with NSCLC. 
Dasatinib synergizes with anti- PD-1 to impair tumor 
growth in NSCLC experimental models. This study provides 
the preclinical rationale for the combined use of dasatinib 
and PD-1/programmed death- ligand 1 blockade to 
improve outcomes of patients with NSCLC.
INTRODUCTION
The emergence of immune- checkpoint 
inhibitors (ICIs) for the treatment of patients 
with non- small cell lung cancer (NSCLC) has 
greatly transformed the management of this 
disease. The most successful strategy hitherto 
consists of the use of antiprogrammed cell 
death 1 (PD-1) antibody to enhance T- cell 
activation and reduce tumor immunosup-
pression.1 Pembrolizumab, nivolumab and 
atezolizumab are Food and Drug Adminis-
tration (FDA)- approved antibodies to block 
the PD-1/programmed death- ligand 1 (PD- 
L1) axis in patients with advanced NSCLC as 
first- line or second- line therapy.1 2 However, 
in spite of the striking long- lasting clinical 
responses previously unseen with other strat-
egies, current immunotherapy only benefits 
30%–40% of the patients when applied in 
monotherapy, and many of the responders 
will develop acquired resistance over the 
course of the treatment.3 4 In addition, 
there is no reliable biomarker to predict 
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response, with PD- L1 expression and tumor mutational 
burden as possible (but not completely accurate) indi-
cators of efficacy.5 The mechanisms of resistance are not 
fully elucidated, but the presence of an immune desert 
tumor microenvironment (TME), with low infiltration 
of effector cytotoxic CD8+ cells, and high infiltration of 
regulatory T cells (Tregs) or myeloid- derived suppressor 
cells are cornerstones of this process.6
Because of these hurdles, novel strategies are actively 
being searched to find ways to reinvigorate the immune 
response. Combination strategies are aimed to eliminate 
the immunosuppressive microenvironment with the 
major goal of eliciting synergistic antitumor effects. Many 
clinical trials are evaluating the combined effect of anti- 
PD-1/PD- L1 therapy with other treatments, including 
chemotherapy, radiotherapy, other immunotherapeutic 
approaches or targeted therapies.7 One of the drugs that 
has been shown to modulate the TME, turning it into 
immunoresponsive is dasatinib, a multikinase inhibitor 
that targets SRC family kinases (SFKs) and BCR/ABL 
kinases and is approved for the treatment of chronic 
myelogenous leukemia (CML) and acute lymphoblastic 
leukemia (ALL).8 In patients with leukemia, dasatinib 
has been shown to cause clonal expansion of CD8+ T 
lymphocytes and natural killer (NK) cells.9 10 Although 
dasatinib as a single agent showed modest clinical efficacy 
in patients with NSCLC in comparison with those under-
going chemotherapy, marked activity or stable disease was 
found in 11.7% patients, suggesting that there is a poten-
tial subpopulation of patients with high sensitivity to 
this drug.11 In preclinical murine models of melanoma, 
sarcoma, breast and colorectal cancer, dasatinib has 
been shown to cause antitumor effects by increasing the 
number of tumor- infiltrating CD8+ cells and decreasing 
that of Tregs.12 In addition, in DDR2- expressing synge-
neic mouse models, dasatinib demonstrated synergistic 
effects with anti- PD-1 therapy.13 Nonetheless, the effect 
of dasatinib in NSCLC, in combination with immuno-
therapy, has not been explored.
Beyond the modulatory effect on the TME, it is well 
established that dasatinib also exerts remarkable direct 
effects on cancer cell growth in many solid tumors. In 
these malignancies, dasatinib inhibits the activity of 
various SFK members, such as SRC, YES, FYN and LYN, 
thereby inducing tumor cell cytotoxicity and apoptosis.8 
We have previously demonstrated in NSCLC that dasat-
inib has a potent antiprimary tumor and antimetastatic 
activity in xenografts established with human cell lines 
and patient- derived xenografts (PDXs) that specifically 
express high levels of YES1.14 These data strongly support 
that YES1 could emerge as an appropriate biomarker of 
response to dasatinib in NSCLC.
We herein demonstrate that YES1 expression is found, 
among other SFK members, as the strongest predictor of 
poor prognosis in patients with NSCLC, and that high 
YES1 protein levels are associated with increased number 
of tumor- infiltrating Tregs. We also show in two different 
and clinically relevant NSCLC mouse models that the 
combination of dasatinib with anti- PD-1 has synergistic 
antitumor effects, leading to tumor regressions. Such 
effects are accompanied by a reduction in the number 
of Tregs within the tumors, which is likely due to an inhi-
bition of Treg conversion and proliferation elicited by 
dasatinib, as we show here in vitro.
MATERIALS AND METHODS
Cohort of patients with NSCLC used for immunophenotyping 
and immunohistochemistry
Surgical samples from primary lung cancer were obtained 
from University Clinic of Navarra (CUN) (Pamplona, 
Spain). We included untreated patients diagnosed with 
NSCLC, with complete resection of the primary tumor 
after surgery. Tumors, classified according to the World 
Health Organization 2004 system, were stratified in agree-
ment with the eighth TNM edition.15 The cohort included 
116 patients diagnosed from 2000 to 2013. Reported 
Recommendations for Tumor Marker Prognostic Studies 
criteria were followed.16 Detailed clinical and patholog-
ical information of the cohort is summarized in online 
supplemental table 1.
Multiplexed immunophenotyping and immunohistochemistry
Paraffin- embedded tissue microarrays (TMAs) containing 
three representative tissue cores per case were built and 
sectioned. For the multispectral immunophenotyping 
of human CD8, CD4, FOXP3 and DAPI (for nuclear 
staining) in the TMAs, we used a validated kit from 
Akoya Biosciences (Marlborough, Massachusetts, USA), 
according to the manufacturer’s recommendation. For 
multispectral immunophenotyping in mouse tumors, 
the murine- specific kit from Akoya (NEL840001KT) 
was used following the manufacturer’s instructions, with 
some modifications and additional markers. The kit 
includes the Alexa Fluor tyramides Opals 520, 570 and 
690, as well as spectral DAPI. Opals 540 (FP1494001KT), 
620 (FP1495001KT) and 650 (FP1496001KT) were not 
included in the kit and were purchased from Akoya. The 
following primary antibodies were used: anti- FOXP3, anti- 
CK, anti- CD31, anti- CD4, anti- CD8 and anti- F4/80. Anti-
bodies and experimental details of human and mouse 
immunophenotyping can be found in online supple-
mental table 2. The sample scanning, spectral unmixing 
and quantification of signals were conducted with the 
Vectra Polaris Automated Quantitative Pathology Imaging 
System (Akoya), using the Phenochart and InForm V.2.4 
softwares (Akoya). Data were given as number of cells 
with a specific immunophenotype/total number of cells.
For the detection of YES1 in the TMAs by immunohis-
tochemistry, antigen retrieval was performed by heating 
the samples in citrate buffer (10 mM, pH 6), and the 
primary anti- YES1 antibody (Proteintech, 20 243–1- AP) 
was incubated at 1:100 dilution. For quantification, slides 
were scanned with the Aperio CS2 scanner (Leica, Barce-
lona, Spain) and images were visualized with the Aperio 
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Image Scope V.12.1.05029. The H- score was then calcu-
lated following previously published protocols.17
Cohort of patients with NSCLC to study expression of SFK 
members: bioinformatic analysis
The description of the cohort and the bioinformatic anal-
ysis are described in online supplemental material and 
methods.
Tumor microenviroment profiling in patients with NSCLC from 
TCGA using CIBERSORT
The details of the methodology used are described in 
online supplemental material and methods.
Cell lines
Previously characterized murine cell lines used for func-
tional experiments were 393P18 19 and UNSCC680AJ 
(from now on referred to as UN680).20 393 P cells were a 
generous gift from Dr JM Kurie (The University of Texas 
MD Anderson Cancer Center, Houston, Texas, USA). 
cDNA from 393P, UN680, Lewis lung carcinoma (3LL)21; 
Lacun2 and Lacun322; and UNSCC679AJ (UN679 for 
simplification)20 was obtained in our Laboratory. cDNA 
from 334SQ, 389N1, 368T1, 389T2, 482N1, 482T1, 
802T4, LKR10, LKR13, and LSZ223 was kindly donated by 
Dr Silvestre Vicent (CIMA). Cells were grown in RPMI-
1640 (Gibco) or DMEM (Gibco) supplemented with 10% 
of HyClone Serum (Thermo Scientific), 1% penicillin–
streptomycin (Lonza), at 37°C in 5% CO2 humidified 
atmosphere.
Cytotoxicity assay
The protocol of the assay is explained in online supple-
mental material and methods.
Real-time quantitative PCR (RT-qPCR) and western blotting
Primers and antibody specifications are shown in online 
supplemental tables 3 and 4, and the methodology for 
both techniques is described in online supplemental 
material and methods.
YES1 knockdown in the 393P cell line
The short hairpin RNA (shRNA) strategy, reagents and 
protocols are shown in online supplemental material and 
methods.
Mouse models
All animal experiments were approved by the Animal 
Committee of the University of Navarra. Murine 
adenocarcinoma 393P (4×106 cells) or squamous cell 
carcinoma UN680 (2×106 cells) cell lines were subcu-
taneously injected in one flank of 8- week- old female 
Sv/129 (Envigo) or A/JOlaHsd (Harlan- Winkelmann) 
mice, respectively. When tumor volume reached approx-
imately 75 mm3, mice were randomized into four groups 
(eight per group) and treated with 30 mg/kg of dasatinib 
(Bristol- Myers Squibb) per day by oral gavage or vehicle 
(80 nM citric acid, pH 2.1; Sigma- Aldrich). The mouse- 
specific anti- PD-1 blocking antibody (RMP1-14, BioXCell) 
was administered the first day of dasatinib treatment (day 
0) and at days 3 and 6 (100 µg per mouse, intraperitone-
ally). Tumor volume was measured with a digital caliper 
every 2 or 3 days and was calculated using the formula 
volume=(length×width2)/2.
A rechallenge experiment was carried out 2 months 
after tumor disappearance (seven mice from the 
combined group and five from the dasatinib group). 
Mice were subcutaneously injected with 393 P cells (2×106 
cells) in the opposite flank, where the tumor was induced 
the first time. Six mice were injected for the first time as 
control group.
The effect of knocking down YES1 in tumor cells, in 
combination with anti- PD-1, was studied in an in vivo 
experiment with 393P- shRNA- transduced cells. We subcu-
taneously injected 4×106 cells in 8- week- old female Sv/129 
mice (Envigo) (n=8 per group). Anti- PD-1 was adminis-
tered at days 6, 9 and 12. Tumor volumes were measured 
as previously explained.
Depletion of CD8 (anti- mouse CD8α, clone 2.43, BioX-
cell), CD4 (anti- mouse CD4, clone GK1.5, BioXcell) or 
NK (anti- mouse NK1.1, clone PK136, BioXcell) cells was 
achieved by intraperitoneal injection of 100 µg of anti-
bodies each time (n=4 injections).
The antitumor effect of dasatinib (30 mg/kg) was also 
tested in mice devoid of T cells. To this aim, 3×1 06 393 P 
cells were inoculated in the flank of 8- week- old female 
athymic nude mice (Harlan- Winkelmann, eight mice per 
group).
Flow cytometry analysis
Sv/129 mice were inoculated with 4×1 06 393 P cells. At 
day 4, daily treatment with dasatinib was initiated (30 mg/
kg) and anti- PD-1 (100 µg per mouse) was injected at days 
4, 7 and 10 from cell inoculation. On day 14, tumors 
and spleens were surgically excised, mechanically disag-
gregated and digested with collagenase (400 MandL 
units/mL, Roche) and DNase (10 mg/mL, Roche). 
Next, erythrocytes were lysed (lysis buffer: 155 mmol/L 
NH4Cl and 10 mmol/L KHCO3) and cell suspensions 
were preincubated with a monoclonal antibody targeting 
mouse CD16/CD32 (15 min RT, FcBlock, 2.4G2; BD 
Pharmingen). Extracellular staining was performed by 
incubating with fluorochrome- conjugated antibodies 
(15 min at 4°C) diluted in FACS buffer (0.1% azide, 1% 
bovine serum albumin in phosphate- buffered saline). All 
antibodies used are shown in online supplemental table 
5. For intracellular staining, cell suspensions were fixed 
and permeabilized according to manufacturer’s instruc-
tions (eBioscience) and then labeled with anti- FOXP3 
antibody (30 min at 4°C). Samples were acquired using a 
FACSCANTO II flow cytometer. Data were analyzed with 
FlowJo software. The gating strategy for the flow cytom-
etry analysis is shown in online supplemental figure 4. 
Depletion of CD8+, CD4+ or NK1.1+ cells was validated in 
blood and spleen samples from mice using flow cytometry, 
as described previously. The effect of treatments on circu-
lating immune cell populations (CD45+, CD8+, CD4+, 
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CD25+ and FOXP3+ cells) was evaluated at day 16 in an 
independent in vivo experiment (eight mice per group) 
after administration of dasatinib (30 mg/kg), anti- PD-1 
(100 µg per mouse) or the combination of both drugs.
The effect of dasatinib on interferon gamma (IFN-γ)- 
induced PD- L1 expression in 393P and UN680 tumor 
cells was studied by flow cytometry. Briefly, 50 000 cells 
were seeded and treated with dasatinib for 72 hours and 
murine IFN-γ (500 U/mL, #315–05, Pepotrech) during 
the 24 hours prior to sample acquisition. Cell staining was 
performed with an anti- mouse PD- L1 antibody, at 1:500 
dilution (MIH5, Thermo Fisher).
IFN-γ-based enzyme-linked immunospot (ELISpot)
The detailed method is described in online supplemental 
material and methods.
Treg isolation and proliferation assay
Treg cells were isolated from murine spleens of the previ-
ously characterized B6- Foxp3EGFP/B6.Cg-Foxp3tm2(EGFP)
Tch/J (Foxp3GFP for short) reporter mice24 (Jackson Labs, 
stock #006772) using a FACSAria- Ilu cell sorter. After 
3 hours of resting, 4×104 Treg cells were seeded in 96- well 
plates in the presence of plate- bound anti- CD3 (1 µg/mL, 
BD Pharmingen) and anti- CD28 antibodies (0.5 µg/mL, 
BD Pharmingen), IL-2 (100 U/mL) and dasatinib (2 and 
10 nM). After 48 hours of incubation with dasatinib, Tregs 
were fixed, permeabilized and stained with anti- ki67 anti-
body (1:400, clone: 16A8, BioLegend). Dead cells were 
identified with Zombie NIR dye (1:2000, BioLegend) and 
were excluded from the analysis.
For the study of Treg cell signaling by western blot-
ting, 7.5×104 Foxp3GFP+ cells were incubated with 10 nM 
of dasatinib for 45 min. Antibodies and their specifica-
tions of use are shown in online supplemental table 4. 
IL-10 levels were measured in cell supernatants using the 
mouse IL-10 ELISA Set, OptEIA (BD Biosciences).
CD4 purification and conversion into Treg cells
The effect of dasatinib on the conversion of CD4+ T 
lymphocytes into Treg cells was determined by flow cytom-
etry and by western blotting. For this purpose, purified 
CD4+ cells were isolated from spleens of the Foxp3GFP 
reporter mice using a CD4+ T- cell isolation kit (Miltenyi 
Biotec) according to the manufacturer’s instructions. 
6×104 (for flow cytometry) or 1×106 (for western blot) 
CD4+ T cells were seeded in the presence of anti- CD3 
and anti- CD28 antibodies, IL-2 (as described previously), 
transforming growth factor beta (TGF-β) (5 ng/mL, 
Peprotech) and dasatinib (2, 10 and 20 nM). For flow 
cytometry analysis, T cells were stained with anti- CD4 
(1:500, RMA4-5, BioLegend) and Zombie NIR dye. Anti-
bodies used for western blotting are specified in online 
supplemental table 4.
Statistical analysis
Comparisons between two groups were performed using 
Student’s t- test when data followed a normal distribu-
tion or Mann- Whitney U test as non- parametric assay. 
Differences between more than two groups were analyzed 
with one- way or two- way analysis of variance followed by 
Bonferroni post hoc test. Statistical tests are specified in 
each figure. For Kaplan- Meier analysis using the publicly 
available datasets, the median cut- off value was used to 
stratify patients in high versus low levels. The log- rank test 
was used to calculate the statistical differences between 
Kaplan- Meier curves.
Data were analyzed with GraphPad Prism V.5 software 
(GraphPad). Statistical significance was defined as p<0.05 
(*), p<0.01 (**) and p<0.001 (***).
RESULTS
High YES1 expression is associated with infiltration of Tregs 
and predicts poor prognosis in patients with NSCLC
We first studied mRNA levels of the SFK members 
expressed in solid tumors (YES1, SRC, FYN and LYN) and 
compared levels between normal lung tissues and NSCLC 
specimens in the TCGA cohort. YES1 and SRC levels 
were significantly higher in NSCLC as compared with 
non- malignant tissues (figure 1A). By contrast, no differ-
ences were found for LYN, and lower expression of FYN 
was observed in tumors than in normal lung (figure 1A). 
We next assessed the prognostic significance of each 
SFK member individually or as an SFK signature using 
the Kaplan- Meier plotter, stratifying the patients by the 
median expression value. Survival analysis showed that 
high YES1 levels were significantly associated with shorter 
overall survival (OS) (HR 2, 95% CI 1.25 to 3.23; p=0.0034; 
figure 1B). High LYN levels were similarly associated with 
reduced OS, although with less prognostic value than that 
of YES1 (HR 1.62, 95% CI 1.02 to 2.58; p=0.039) (online 
supplemental figure 1A). SRC expression was not related 
to prognosis and low FYN levels predicted worse outcome 
(not shown). The signature including all these SFKs was 
also weakly but significantly associated with worse OS (HR 
1.62, 95% CI 1.02 to 2.57; p=0.041) (figure 1C). There-
fore, we conclude that YES1 is the strongest predictor of 
reduced OS in NSCLC, among all these SFKs.
Based on these results, we hypothesized that high YES1 
levels could be associated with a more immunosuppressive 
TME, which could explain the worse outcome of patients 
with high levels of YES1. To address this, we used a series 
of 116 patients from CUN and quantified YES1 protein 
expression together with the immune markers CD4, CD8 
and FOXP3. YES1 was evaluated by immunohistochem-
istry after calculation of the H- score, whereas the rest 
of the markers were analyzed by quantitative multiplex 
immunophenotyping using the Vectra Polaris System. 
The YES1 H- score was stratified by quartiles to classify 
patients into high (upper quartile) versus low (75% of 
patients below the upper quartile) expression. Interest-
ingly, those patients with high YES1 levels showed also 
significantly higher number of tumor- infiltrating Tregs 
(FOXP3+/CD4+ cells) (p=0.041, figure 1D), suggesting 
that tumors with YES1 expression tend to be more immu-
nosuppressive. When comparing the upper quartile 
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versus the lowest quartile (25% of patients with the lowest 
YES1 expression), the differences in the number of Tregs 
were even more pronounced (p=0.009, figure 1E). More-
over, we found that this association occurred in patients 
with lung adenocarcinoma (LUAD) but not in those with 
lung squamous cell carcinoma (LUSC) (figure 1F,G and 
online supplemental figure 1B,C). On the contrary, no 
relationship between expression of YES1 and CD4+/
FOXP3− or CD8+ cells was found (online supplemental 
figure 1D,E). Representative images of tumors with high 
versus low YES1 levels and high versus low number of 
CD4+/FOXP3+ cells are shown in figure 1H.
Figure 1 (A) Comparison of YES1, SRC, FYN and LYN mRNA expressions between non- malignant lung tissue and NSCLC 
(TCGA cohort). Mann- Whitney U test was used for the statistical analysis. (B,C) Kaplan- Meier survival curves showing that high 
YES1 and SFK levels (above the median) are associated with worse OS in NSCLC. The log- rank test was used for the statistical 
comparisons. (D,E) Quantification of FOXP3+CD4+ cells in NSCLC specimens from the CUN cohort. The percentage of Tregs 
(FOXP3+CD4+) in YES1- positive tumors in the upper quartile of the YES1 H- score is significantly higher than that found for the 
rest of the tumors (D) and in the lower quartile (E). (F,G) Quantification of FOXP3+CD4+ cells in patients with LUAD from CUN. 
The percentage of Treg cells in the YES1 upper quartile was compared with the rest of the quartiles (F) or the lower quartile (G). 
(H) Representative images of YES1 IHC and multiplex immunofluorescence for CD8+, CD4+ and FOXP3+CD4+ cells in patients 
with NSCLC. (I) Relative abundance of Treg cells in patients with LUAD from the TCGA database analyzed with CIBERSORT 
tool. Scale bar: 50 µm. (D–G,I) Data are expressed as median, and statistical comparisons were performed using the Mann- 
Whitney U test. *P<0.05, **P<0.01. CUN, University Clinic of Navarra; IHC, immunohistochemistry; LUAD, lung adenocarcinoma; 
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In order to validate these results, we performed an in 
silico analysis using data from TCGA and CIBERSORT,25 
a computational tool that infers the presence of specific 
immune cell populations in a given patient based on 
gene expression tumor profiles associated with a specific 
immune cell type. This analysis showed that patients 
with LUAD with high YES1 expression tended to have 
a higher number of Treg cells, although this difference 
did not reach statistical significance (p=0.055, figure 1I). 
There was no association between YES1 expression and 
the number of Treg cells in LUSC (online supplemental 
figure 1F).
SKF expression in murine NSCLC cancer cell lines and in vitro 
effect of dasatinib
Then we sought to select immunocompetent NSCLC 
mouse models that were appropriate to investigate the 
immunomodulatory effect of dasatinib in vivo, with or 
without combination with anti- PD-1 therapy. Recent 
studies have shown the direct antiproliferative effect of 
this SFK inhibitor on tumor cells, as well as its role in 
altering the immunosuppressive TME.12 In addition, we 
have previously shown that YES1 is an accurate predictor 
of response to dasatinib in NSCLC.14
We screened a panel of murine NSCLC cell lines (n=16), 
including adenocarcinoma and squamous cell carcinoma 
histologies and quantified mRNA levels of the SFK family 
members. RT- qPCR revealed that most cell lines showed 
expression of YES1, SCR, FYN and LYN, although with 
different mRNA levels (figure 2A). We also confirmed by 
western blotting the protein expression of YES1 in some 
of the cell lines (n=9) (figure 2B) and selected 393P and 
UN680 cells for further experiments, due to high YES1 
levels and their response to anti- PD-1 therapy in vivo, 
according to our previous results.19 20
Figure 2 (A) mRNA expression of YES1, SRC, FYN and LYN analyzed by RT- qPCR in a panel of 16 murine NSCLC cell 
lines. (B) Western blot analysis of YES1 expression in nine murine cell lines. (C) Effect of dasatinib on 393P and UN680 cell 
proliferation in vitro. (D) Western blot analysis showing pSFK protein inhibition by dasatinib at 10 hours post- treatment in vitro. 
(E) Subcutaneous tumor growth of 393 P cells injected in athymic nude mice treated with dasatinib (30 mg/kg) or vehicle. A two- 
way analysis of variance followed by a post hoc Bonferroni test was used. *P<0.05, ***P<0.001. NSCLC, non- small cell lung 
cancer; pSFK, phospho- SRC family kinase; RT- qPCR, real- time quantitative PCR; SFK, SRC family kinase.
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The direct effect of dasatinib on proliferation was then 
evaluated in vitro for 393P and UN680 cells. Both cell 
lines responded to dasatinib in a dose- dependent manner 
(figure 2C) with an IC50 of <2 µM, similar to what has 
been described for SFK- expressing human cancer cells.14 
On- target specificity of dasatinib treatment was verified by 
western blot analysis of SFK phosphorylation. As shown in 
figure 2D, a decrease in phospho(p)- SFKs was observed 
on dasatinib administration (20 nM–15µM). Of note, 
there is currently no antibody to detect specifically the 
phosphorylated form of YES1. As dasatinib may also affect 
the lymphocyte- specific protein tyrosine kinase (LCK) of 
T cells,26 which can partially mediate its antitumor effects, 
we performed an in vivo experiment where 393 P cells 
were injected into athymic nude mice (lacking T cells) 
that were treated with 30 mg/kg dasatinib. Results showed 
that dasatinib exerted a significant therapeutic effect, 
with a 51% reduction in tumor volume compared with 
controls (figure 2E and online supplemental figure 1G).
Dasatinib synergizes with anti-PD-1 immunotherapy in NSCLC 
causing tumor regression
The in vivo effect of dasatinib alone or in combination 
with anti- PD-1 was then assessed in the two immunocom-
petent NSCLC models. In the 393P subcutaneous adeno-
carcinoma model, treatment with dasatinib resulted in 
a highly significant reduction in tumor volume (~70% 
at day 35 postcell injection with respect to controls), 
whereas anti- PD-1 showed a modest decrease (~24%) 
(figure 3A). The combination of dasatinib with anti- PD-1 
caused a dramatic reduction of tumor growth (p<0.001), 
with seven out of eight complete tumor rejections 
(figure 3A,B). OS of mice was significantly prolonged 
in dasatinib- administered mice, but was increased much 
further for the combination group, with seven animals 
(87.5%) alive at the end of the study (100 days after cell 
injection) (figure 3C).
A rechallenge experiment was performed 60 days after 
tumor rejections to test immunological memory. All mice 
coming from anti- PD-1 (n=1), dasatinib (n=4) and dasat-
inib+anti- PD-1 (n=7) groups were refractory to the devel-
opment of new tumors (figure 3D, anti- PD-1 not shown). 
Then, an ELIspot assay was carried out by culturing 
splenocytes from these mice with irradiated 393 P cells. 
As shown in figure 3E, IFN-γ secretion by T cells was 
significantly higher (p<0.05) in the dual- treatment group 
compared with anti- PD-1 or dasatinib alone, suggesting 
a more effective long- lasting memory response when 
combining dasatinib and anti- PD-1. Tumor growth for 
each one of the animals in shown in online supplemental 
figure 1H.
Assessment of pSFK levels and some of the downstream 
molecules related to dasatinib activity was carried out by 
western blot analysis in tumors from the different exper-
imental groups in an independent short- term treatment 
in vivo experiment (see further). As shown in online 
supplemental figure 2A,B, levels of pSFK were strongly 
reduced in the combination group, with a more modest 
decrease in the single- treatment groups. No changes were 
observed for the other phosphoproteins tested: pAKT, 
pSTAT3 and pERK1/2.
We also studied the effect of this drug combination in 
an alternative NSCLC model: a squamous cell carcinoma 
syngeneic mouse model developed by subcutaneous 
injection of UN680 cells, previously developed and char-
acterized in our laboratory.20 Although the combinatory 
effect was less pronounced in this model, results were 
similar to the 393P model, with therapeutic improve-
ment for the combination between dasatinib and anti- 
PD-1 (figure 3F,G and online supplemental figure 1I). 
In this case, one tumor regression was achieved in the 
experiment, corresponding to the combination group 
(figure 3G).
No weight loss or external signs of toxicity, such as 
lordosis or distress, were observed in the single- treated or 
combined- treated groups of animals.
To ascertain to what extent expression of YES1 in cancer 
cells was mediating the therapeutic effect, we silenced 
YES1 in 393 P cells using shRNA and performed an in 
vivo experiment with or without combination with anti- 
PD-1 (online supplemental figure 2C,D). As expected, 
YES1 knockdown improved anti- PD-1 efficacy, obtaining 
a 52% reduction in the tumor volume for the shYES1+ 
anti- PD-1 group compared with the untreated controls 
(sh- scramble) and 41% with respect to the sh- scramble 
+anti- PD-1 treated group (online supplemental figure 
2C,D).
Combination of dasatinib and anti-PD-1 reduces Treg cells in 
the TME and blood
Changes in the tumor immune infiltrate for the different 
experimental groups were assessed by flow cytometry in 
the 393P model in an additional (short- term treatment) 
in vivo experiment, where tumor samples were obtained 
at day 14, time at which tumor volume curves from the 
different groups begin to separate (figure 4A and online 
supplemental figure 3A). Dasatinib and/or combina-
tion treatments led to a very significant decrease in the 
number of Tregs (CD4+CD25+FOXP3+) and levels of 
PD-1 in CD8+ and in CD4+ cells (the latter ones likely 
reflecting exhausted T lymphocytes) (figure 4B–D). We 
also observed significantly lower levels of GITR (another 
marker of Tregs) in CD4+ cells, but only in those mice 
treated with dual blockade (figure 4E). None of the treat-
ments alone or in combination modified the frequency 
of CD45+, CD4+, CD8+, NK cells or macrophages 
(figure 4F–H and online supplemental figure 3B–I). The 
gating strategy followed for the analysis of lymphocyte 
subpopulations can be found in online supplemental 
figure 4. Levels of the Treg- associated cytokine IL-10 were 
also significantly reduced in tumors from animals admin-
istered with the drug combination (figure 4I). In addi-
tion, we studied whether dasatinib modified PD- L1 levels 
in either 393P or UN680 cells in vitro, but no changes 
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In order to further investigate changes in the tumor 
immunolandscape due to the different treatments, we 
performed in situ multiplex immunofluorescence quan-
tification of CD4, CD8, F4/80, CD31 and FOXP3 infil-
trating cells in 393P tumors. Interestingly, consistent 
with the flow cytometry results, the combined treatment 
dasatinib+anti- PD-1 led to a significant decrease in the 
number of Treg cells (figure 5A). Representative images 
of FOXP3+/CD4+ cells are shown in figure 5B and a 
representative picture of a wide- field tumor where all 
seven markers are merged, in figure 5C. A lower number 
of CD31+ cells was also detected in animals administered 
with anti- PD-1 and the combination treatment, suggesting 
an impaired angiogenesis in these groups. No changes 
with respect to controls were observed for the other cell 
populations (online supplemental figure 5A–E).
We next evaluated whether dasatinib alone or in combi-
nation with anti- PD-1 would not only decrease the infiltra-
tion of Tregs in the TME but also deplete circulating Tregs. 
For this purpose, we quantified CD4+, CD8+ and CD4+/
Figure 3 (A) Subcutaneous tumor volume in the 393P model (Sv/129 mice) treated with dasatinib (30 mg/kg/day), anti- PD-1 
(100 µg, days 7, 10 and 13), or both (n=8). Statistical differences are indicated for the comparisons between double- treated 
and control groups. (B) Waterfall plot showing the individual tumor volume changes between days 7 and 35 in the 393P model. 
(C) Survival curves of the in vivo experiment shown in (A). Log- rank test was used for statistical analysis. A final volume of 
1000 mm3 was used as endpoint criteria. (D) Rechallenge experiment using 393 P cells injected in tumor- rejected mice, 60 
days after tumor disappearance. Naïve mice were used as control group (n=6). (E) Analysis of 393P- specific IFN-ɣ secretion 
by splenocytes isolated from the mice of the rechallenge experiment. IFN-ɣ levels were measured using ELIspot technique. 
Student’s t- test was used for comparison. (F) Tumor growth of UN680 cells implanted in A/JOlaHsd mice and treated with 
dasatinib (30 mg/kg, daily), anti- PD-1 (100 µg, days 5, 8 and 11), or both (n=8). (G) Waterfall plot of the volume changes in 
UN680 tumors between days 5 and 16. (A,F) Data are expressed as mean±SEM and were analyzed with a two- way analysis 
of variance followed by a post hoc Bonferroni test. Statistical differences show the comparison between controls versus the 
double- treatment group. *P<0.05, **P<0.01, ***P<0.001. ELIspot, enzyme- linked immunospot; IFN-γ, interferon gamma; PD-1, 
programmed cell death 1.
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FOXP3+/CD25+ cell populations in blood, in an inde-
pendent in vivo experiment, at day 16 (figure 5D–G 
and online supplemental figure 5F). Interestingly, Treg 
cells were prominently reduced in the dasatinib and the 
combination groups (figure 5E). No changes were found 
in the number of Tregs in anti- PD-1 treated mice, which 
shows that the depletion of these cells is mainly mediated, 
at least in blood, by dasatinib monotherapy. Levels of CD4 
and CD8 T cells remained unchanged with any of the 
treatments (figure 5F,G).
CD4+ and CD8+ T-cell depletions diminish the effect of 
dasatinib and anti-PD-1 on tumor growth
To assess which immune populations were involved in the 
response to dasatinib and anti- PD-1 in vivo, we selectively 
depleted CD4, CD8 or NK lymphocytes in mice bearing 
393P tumors (figure 6A,B). T cells and NK cells were 
depleted 24 hours prior to the treatment initiation. Levels 
of cell depletion were tested in blood and spleen by flow 
cytometry at the end of the experiment. An example of 
the drop in CD8+ population in treated animals is shown 
in online supplemental figure 6A. All groups responded 
to the combination treatment compared with controls 
until day 12. This delay in tumor growth could be asso-
ciated with the direct effect of dasatinib on tumor cell 
proliferation. However, from that time point on, dasatinib 
and anti- PD-1 effectiveness was significantly abrogated in 
CD4- depleted and CD8- depleted mice, demonstrating 
that these subpopulations of cells are required for the 
antitumor activity of the combined therapy (figure 6A,B).
Dasatinib impairs proliferation and inhibits LCK 
phosphorylation in Treg cells
We investigated whether dasatinib could exert an anti-
proliferative effect on Treg cells, as seen in tumor cells. 
Dasatinib effectively diminished Treg proliferation at 
very low doses (2 and 10 nM) (figure 6C). This decrease 
was accompanied by a very significant reduction in IL-10 
levels released by these cells (figure 6D). We next assessed 
the molecular mechanism behind the effect of dasatinib 
Figure 4 (A) Tumor volumes of 393 P cells, at the moment of conducting the flow cytometry assay (day 14). Mice were treated 
with dasatinib (30 mg/kg/day), anti- PD-1 (100 µg, days 4, 7 and 10), or both (n=8). (B–H) Percentage of cells or MFI of tumor 
immune populations: tumor- infiltrating Treg (FOXP3+CD25+CD4+) (B), PD-1 in CD8+ (C), PD-1 in CD4+ (D), GITR in CD4+ (E), 
CD45+ (F), CD8+/CD45+ (G) and CD4+/CD45+ (H) cells. (I) mRNA expression of IL-10 in 393P tumors. Data are represented as 
mean±SEM. Comparisons were analysed using a one- way analysis of variance followed by a posthoc Bonferroni test. *P<0.05, 
**P<0.01, ***P<0.001. IL, interleukin; MFI, median fluorescence intensity; PD-1, programmed cell death 1; Treg, regulatory T cell.
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on Treg cell proliferation. To this aim, we studied acti-
vation of the LCK, a direct target of dasatinib, whose 
phosphorylation at Y394 is necessary for TCR signaling 
initiation.27 A strong inhibition of pLCK levels was found 
in the Treg cells treated with dasatinib (10 nM) compared 
with untreated cells (figure 6E). YES1 protein was also 
detected in Tregs, although levels were lower than those of 
LCK. Direct targeting on YES1 phosphorylation by dasat-
inib in Tregs could not be studied due to lack of specific 
anti- phosphoYES1 antibodies. Under these conditions, 
dasatinib did not alter pSTAT3 nor pSTAT5 levels in Treg 
cells (figure 6E and online supplemental figure 6C).
Dasatinib blocks CD4 T-cell conversion into Treg cells in vitro
We next evaluated whether the decrease in the 
percentage of Tregs observed in 393P tumors could be 
due not only to an inhibition of Treg cell proliferation 
but also to a blockade of the conversion of effector CD4+ 
T cells into Tregs. For this purpose, CD4+ CD25- cells 
were cultured with TGF-β to induce their differentiation 
into Treg cells (CD4+CD25+FOXP3+), according to stan-
dard protocols,28 in the presence of dasatinib. Remark-
ably, CD4+CD25- cell conversion was strongly reduced 
by dasatinib in a dose- dependent manner (figure 6F,G), 
suggesting that the drop observed in the number of 
Figure 5 (A) Quantification of cells coexpressing FOXP3 and CD4 (Treg cells) in 393P tumor microenvironment (n=8) analyzed 
by mIF. (B) Representative mIF images showing Treg cells in each group. (C) Example of an mIF landscape image showing CK+, 
CD8+, CD4+, F4/80+, CD31+ and FOXP3+ cells in one of these tumors. (D) 393P tumor volumes at the time (day 16) of the 
characterization of circulating immune cells by flow cytometry. (E–G) Percentage of Tregs (E), CD8+ (F) and CD4+ (G) cells in 
blood. Differences were analyzed with one- way analysis of variance followed by a post hoc Bonferroni test. *P<0.05, **P<0.01, 
***P<0.001. mIF, multiplex immunofluorescence; PD-1, programmed cell death 1; Treg, regulatory T cell.
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Figure 6 (A) Schematic representation of the experimental design followed for the depletion of CD8, CD4 and NK1.1 cell 
populations and the treatment with dasatinib+anti- PD-1 in vivo. (B) Tumor growth of 393P- inoculated cells in the presence of 
depleting antibodies and treatment with dasatinib+anti- PD-1 (n=6). (C) Treg cell proliferation 4 days after plating in the presence 
of IL-2, anti(α)CD3, αCD28 and dasatinib (2 and 10 nM) measured by flow cytometry. (D) IL-10 levels measured in Treg cells 
culture medium after 48 hours of exposure to dasatinib. (E) Protein expression of pLCK, LCK, YES1, pSTAT3, STAT3, pSTAT5 
and STAT5 in Treg cells treated with dasatinib (10 nM) for 45 min. (F,G) In vitro experiment of TGF-β-dependent CD4+ T cell 
conversion into Tregs, in the presence of IL-2, αCD3, αCD28 and dasatinib (2, 10 and 20 nM), analyzed by flow cytometry. (H) 
Western blotting of pSTAT5, STAT5, pSMAD3 and SMAD3 in CD4+ T cells converted into Tregs after treatment with dasatinib 
(10 nM). Differences between groups were evaluated with a two- way (B) or a one- way analysis of variance test (C,D,F) followed 
by a post hoc Bonferroni test. **P<0.01, ***P<0.001, ****P<0.0001. IL, interleukin; LCK, lymphocyte- specific protein tyrosine 
kinase; PD-1, programmed cell death 1; pLCK, phospholymphocyte- specific protein tyrosine kinase; TGF-β, transforming 
growth factor beta; Treg, regulatory T cell.
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tumor- infiltrating Tregs in the dasatinib+anti- PD-1 treat-
ment is mediated by an impairment of CD4 T- lymphocyte 
conversion into Tregs and Treg cell proliferation. Levels 
of pSMAD3/total SMAD3 were subsequently evaluated, 
showing that dasatinib (10 and 20 nM) decreased the 
amount of both the phosphorylated and the total protein 
(figure 6H and online supplemental figure 6C–F). More-
over, dasatinib totally impeded the activation of STAT5 
(figure 6H). Based on these results, we conclude that 
dasatinib inhibits TGF-β-dependent CD4 T- cell conversion 
by diminishing SMAD3- and STAT5- mediated signaling.
Legends of the supplemental figures can be found in 
online supplemental file 3.
DISCUSSION
Research aiming to overcome primary and acquired resis-
tance against anti- PD-1 therapy in patients with NSCLC 
and with other malignancies is currently a priority. In 
fact, more than 1000 clinical trials are assessing combi-
nations of immunotherapy (mainly anti- PD- L1/PD-1 or 
CTLA-4 antibodies) with other therapeutic strategies. 
Some approaches are using immunomodulatory drugs 
to unlock and reactivate the immune system.1 2 However, 
given the large amount and variety of such proposed 
drugs and strategies, the use of appropriate syngeneic 
animal models where these combinations can be easily 
tested offers a great tool that may guide clinical trials. 
Here, we report the successful combination between 
dasatinib (a drug approved by the FDA for leukemia) 
and anti- PD-1 for the treatment of NSCLC in two clini-
cally relevant mouse models. This combination reduces 
the number of tumor- infiltrating Tregs, causing tumor 
regressions and inducing immunological memory, with 
long- lasting response in these animals.
An increasing number of studies is showing that the 
TME immunolandscape is determined by specific genetic 
alterations and expression of certain genes in cancer cells. 
For example, the coexistence of KRAS and STK11 (LKB1) 
mutations, which is estimated in 8%–30% of patients with 
NSCLC, is associated with an immunosuppressive TME 
characterized by high infiltration of tumor- associated 
neutrophils that secrete IL-6 and CXCL-10.29 30 On the 
contrary, concurrent KRAS- TP53 mutations are associ-
ated with infiltration of effector CD8+ T lymphocytes and 
responsiveness to anti- PD-1 therapy.31 Tumor cell- intrinsic 
activation of β-catenin signaling has been linked to a non- 
T- inflamed TME and resistance to anti- PD-1 therapy.32 
Similarly, gain in Myc function inhibits CD4+ T- cell activa-
tion and infiltration.33 34 Here we show that expression of 
the SFK member YES1 in ADC is significantly associated 
with an increase in the number of Tregs in patients with 
NSCLC. This suggests that YES1 induces an immunosup-
pressive TME that could hinder the effect of anti- PD-1 
therapy. Among the SFK members commonly expressed 
in NSCLC, high levels of both YES1 and LYN predicted 
reduced OS in patients with NSCLC, with YES1 being 
clearly the most potent predictor of poor prognosis. This 
is in agreement with a previous report from our group 
showing that YES1 overexpression and gene amplifica-
tion were associated with a reduction in both relapse- free 
survival and OS.14 In our lung cancer models, we have 
shown, using shRNA strategies, that abrogation of YES1 
in tumor cells is responsible for ~50% of tumor reduction 
when combined with anti- PD-1.
Among the drugs that inhibit the SFKs, dasatinib has 
been tested in clinical trials for NSCLC11 and other solid 
tumors. This multityrosine kinase inhibitor is currently 
approved for the treatment of CML and ALL, while its 
effectiveness alone or in combination with other drugs 
in non- hematological malignancies is still under inves-
tigation. A fundamental issue in NSCLC is to accurately 
define biomarkers of drug response, since clinical benefit 
has been found to be restricted to a small percentage of 
patients.5 Huang et al35 identified a six- gene signature 
that predicted sensitivity to dasatinib in lung cancer cell 
lines, although such putative biomarkers have not been 
assessed in patients yet. Dasatinib causes cell growth inhi-
bition and apoptosis in NSCLC cells with high expression 
of YES1, whereas in low- expressing or negative cells, the 
effect is much less pronounced.14 Moreover, a potent 
antitumor effect has been demonstrated in tumor growth 
and metastasis of cell line- derived and PDXs that express 
high YES1 levels.14 Therefore, YES1 is postulated as a 
biomarker of response to dasatinib in NSCLC. In addi-
tion, based on results presented here, effectiveness of 
dasatinib could be monitored in blood as a reduction in 
the number of Treg cells.
Dasatinib exerts direct effects on both cancer cells and 
cells of the TME, as results presented here and reports in 
immunocompetent models of melanoma, sarcoma, breast 
and colorectal cancer have shown.12 Mechanistically, the 
antitumor activity observed in these models was related to 
an increase in the number of infiltrating CD8+ cells and 
reduction of Tregs.12 Tu et al13 have recently reported 
that combination between dasatinib and anti- PD-1 results 
in a synergistic antitumor growth in DDR2- expressing 
murine colon cancer and sarcoma models. In agreement 
with these results, our study, using dasatinib alone or in 
combination with anti- PD-1, has demonstrated a very 
significant drop in the number of Tregs and exhausted 
CD8+ and CD4+ T lymphocytes, especially for the drug 
combination. This is also concomitantly accompanied 
by a decrease in intratumoral levels of IL-10, a cytokine 
released by Tregs with tolerogenic and anti- inflammatory 
properties that dampens immune responses.36 IL-10 
signaling is required for the immunosuppressive role of 
Tregs, altering the efficient activation of T cells.36 37 High 
levels of this cytokine in tumors and serum from patients 
with NSCLC have been found to be related with worse 
outcome.38 39
Depletion experiments revealed that both CD8+ 
and CD4+ T lymphocytes, but not NK cells, are required 
for the effective response to the combined therapy. 
Nonetheless, recovery of tumor growth after CD8+/CD4+ 
depletion was not fully achieved, which argues in favor of 
copyright.
 on O















13Redin E, et al. J Immunother Cancer 2021;9:e001496. doi:10.1136/jitc-2020-001496
Open access
a direct effect of dasatinib on tumor cells, in addition to 
the effect on the T lymphocyte population.
Complex mechanisms may account for the intratumoral 
accumulation of CD4+/FOXP3+/CD25+ Tregs, including 
recruitment, expansion and differentiation from conven-
tional effector CD4+ T lymphocytes.37 In our study, we 
hypothesized that dasatinib could alter proliferation and/
or prevent the conversion from CD4+ cells into Tregs. We 
have proven the novel effect of dasatinib on alteration of 
Treg cell proliferation and conversion from CD4+ cells: a 
dose of as low as 10 nM dasatinib was able to reduce Treg 
proliferation by 96.3% and conversion from CD4 T cells 
by 76.7%. Effects were associated with reduction in levels 
of active LCK, STAT5 and SMAD3. Interestingly, Dyck et 
al40 have shown that anti- PD-1 inhibits Tregs conversion 
to unleash intratumoral effector T cells. Taken together, 
these data suggest that the main mechanism behind the 
effectiveness of combining dasatinib and anti- PD-1 thera-
pies may rely on a full blockade of the Treg proliferation/
conversion by both dasatinib and anti- PD-1, thus taking 
the brakes off the tumor specific cytotoxic effect of T 
lymphocytes.
Although the use of dasatinib in NSCLC alone or in 
combination with chemotherapy or EGFR inhibitors has 
been somewhat disappointing so far, our results provide 
the preclinical rationale for the combined use of dasat-
inib and PD-1/PD- L1 blockade to improve outcomes of 
patients with NSCLC. Of note, the clinical trial FRAC-
TION (NCT02750514) is exploring combination between 
dasatinib and ICI in solid tumors.
CONCLUSIONS
Protein expression of YES1 is associated with poor prog-
nosis and increased numbers of Tregs in patients with 
NSCLC. Dasatinib synergizes with anti- PD-1 to impair 
tumor growth in NSCLC experimental models and 
reduces the number of Tregs. CD8+ and CD4+ lympho-
cytes are necessary for the efficacy of the combination. 
The relevance of these results is that we provide a ratio-
nale for the combined use of dasatinib and anti- PD-1 to 
improve outcomes of patients with NSCLC.
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Supplementary Table 1. Cohort of NSCLC patients from Clinica Universidad de Navarra (n=116) 
used to study the expression of YES1, PDL1, FOXP3, CD4, CD8, CD31 and F4/80 without neo- or 
adjuvant chemo- or radiotherapy. Three patients were not evaluated due to technical issues. 





≤65 61 (53) 




Female 22 (19) 
Male 94 (81) 
  
Stage  
I 107 (92) 
II 6 (5) 




Adenocarcinoma 55 (47) 





Smoking status  
  
Non-smoker 10 (9) 
Former smoker 79 (68) 
Current smoker 27 (23) 
  
 
Supplementary Table 2. Antibodies and conditions used for multispectral immunophenotyping in 




Antibody (Ref) Dilution Antigen retrieval Opal /Dilution 
Foxp3 (CST, 12653) 1:600 Citrate buffer, pH6 540 / 1:500 
CK (CST, 4279) 1:100 TrisEDTA buffer, pH9 690 / 1:100 
CD31 (CST, 77699) 1:400 Citrate buffer, pH6 570 / 1:600 
CD4 (CST, 25229) 1:400 Citrate buffer, pH6 520 / 1:300 
CD8 (CST, 98941) 1:500 Citrate buffer, pH6 620 / 1:100 
F4/80 (CST, 70076) 1:400 Citrate buffer, pH6 650/1:600 
CD8 (Thermo, C8/14bb) 1:400 PerkinElmer reagent, pH6 570 
CD4(Dako, 4B12) Ready to use Dako reagent, pH9 650 
FOXP3 (PE, OP7TL1001KT) 1:300 PerkinElmer reagent, pH6 620 
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Supplementary Table 3. Sequences of the primers employed for RT-qPCR analysis. 
Gene Forward sequence (5’3’) Reverse sequence (5’3’) 
GAPDH ACTTTGTCAAGCTCATTTCC TGCAGCGAACTTTATTGATG 
YES1 GTAAGCCCAAGTGCCAGTCATT GGAAGAGGTCGGGGCAACT 
SRC AGGCTTCAACTCCTCGGAC CTCATAGTCATAGAGGGCCACA 
FYN GGGTGTGAACTCCTCCTCTC TTCCGTCCGTGCTTCATAGT 
LYN TGTGAGAGATCCAACGTCCA TTGTTTGAAATCTCTGTCCTGGT 
IL10 GGACAACATACTGCTAACCG AATCACTCTTCACCTGCTCC 
 
 
Supplementary Table 4. Antibodies and conditions used for Western blot analysis. 
Antibody (anti-) (Ref) Dilution Manufacturer 
YES1 (PA5-72233) 1:2000 ThermoFisher 
pSFKs/pLCK (D49G4) 1:1000 Cell Signaling 
β actin 1:10000 Sigma 
pSTAT3 (Y705) (#9131) 1:1000 Cell Signaling 
STAT3 (#9139) 1:1000 Cell Signaling 
pMAPK (#9101) 1:1000 Cell Signaling 
MAPK (#9102)  1:1000 Cell Signaling 
pAKT (#4060) 1:1000 Cell Signaling 
AKT (#9272)  1:1000 Cell Signaling 
pSMAD3 (#8769) 1:1000 Cell Signaling 
SMAD3 (#5678) 1:1000 Cell Signaling 
LCK (#2752) 1:1000 Cell Signaling 
pSTAT5 (#4322) 1:1000 Cell Signaling 
STAT5 (#9420) 1:1000 Cell Signaling 
 
 
Supplementary Table 5. Antibodies and conditions used for the immunophenotyping of 393P 
tumors by flow cytometry. 
Antibody (anti-) Dilution Clone Manufacturer 
CD45 1:1000 30-F11 BioLegend 
CD8a 1:400 53-6.7 BioLegend 
CD4 1:800 RM4-5 BioLegend 
CD19c 1:400 6D5 BioLegend 
NK1.1 1:20 PK136 BioLegend 
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CD25 1:100 PC61 BioLegend 
F4/80 1:200 BM8 BioLegend 
CD11b 1:400 M1/70 BioLegend 
Ly6C 1:400 HK1.4 BioLegend 
Ly6G 1:400 1A8 BioLegend 
LAG3 1:200 C9B7W BioLegend 
PD-1 1:160 29F.1A12 BioLegend 
GITR 1:200 DTA-1 BioLegend 
PDL1 1:80 10F.9G2 BioLegend 
FOXP3 1:160 3G3 Abcam 
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Cohort of NSCLC patients to study expression of SFK members: bioinformatic analysis 
The Cancer Genome Atlas (TCGA) database was used to study mRNA expression of 
the SFK members YES1, SRC, FYN and LYN in non-tumor lung tissue (n=109) and lung 
cancer specimens (n=1016). Comparisons between non-malignant and malignant samples 
were performed with the U-Mann Whitney test. For survival analyses, the publicly 
available bioinformatic tool Km plotter (https://kmplot.com/analysis) was used following 
previously published recommendations [1] (see below, in this document, for these 
references). This tool includes datasets from TCGA, Gene Expression Omnibus (GEO) and 
the Cancer Biomedical Informatics Grid (caBIG). Criteria for patient’s selection were as 
follows: NSCLC patients from any stage or histological type, who did not receive any 
treatment. Taking into account these criteria, a total number of 227 patients were included 
in the Kaplan-Meier analysis. The median expression was set as cut-off value and overall 
survival was considered up to 60 months.  
Tumor microenvironment profiling in NSCLC patients with CIBERSORT 
TCGA-LUAD (155 cases) and TCGA-LUSC (248 cases) RNAseq gene expression 
data with standard annotation were uploaded to the CIBERSORT web portal 
(http://cibersort.stanford.edu/), and the algorithm was run using the LM22 signature and 
1000 permutations [2]. Only the cases with a CIBERSORT output of p < 0.01, indicating 
that the inferred fractions of immune cell populations produced by CIBERSORT were 
accurate, were selected for further analyses [3,4]. Inferred T regulatory cell and CD8 T cell 
fractions for each TCGA patient, were matched with their corresponding YES1 expression. 
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Subsequent analyses were carried out by stratifying YES1 expression in high (upper 
quartile (Q4)) or low (Q1+Q2+Q3). 
Cytotoxicity assay 
UN680 (500 cells per well) and 393P (500 cells per well) were seeded in 24 well 
plates and dasatinib was added 24h later at different doses. Cell proliferation was 
determined 5 days after dasatinib addition by staining the cells with crystal violet (0.25% in 
methanol:H20 at dilution 1:1) and calculating the percentage of the area stained per well 
with the software Image J. 
Quantitative real time PCR (qPCR) and Western blotting 
RNA extraction, qPCR and Western blot methods were performed as previously 
described [5]. GAPDH was used as endogenous gene for qPCR. Primer sequences for the 
genes studied are shown in Supplementary Table 3. For Western blotting, the primary 
antibodies are specified in Supplementary Table 4. 
YES1 knockdown in the 393P cell line 
shRNAs targeting murine YES1 and a control shRNA were purchased from Sigma 
(TRC23614). Lentiviral particles were produced by transfection of HEK293T cells with 2 
µg of the plasmid of interest in the presence of lentiviral packaging plasmids and X-
tremeGENE HP DNA Transfection reagent (Sigma). Then, viruses were collected and 393P 
cells were infected with 300 µL of lentivirus and 8 µg/mL of polybrene (Sigma). Cells were 
selected with 5µg/mL of puromycin for a week. Finally, YES1 knockdown was checked by 
western blotting.  
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IFN-γ-based enzyme-linked immunospot (ELISpot) 
Splenocytes (7x105) were cultured for 24h in the presence of 7x104 irradiated 393P 
cells in 96 well-ELIIP plates (Millipore) previously coated with anti-IFN-γ antibody (clone 
AN-18; 1:250; Mabtech). Then, wells were washed and incubated with a biotinylated anti-
IFN-γ antibody (clone R4-6A2; Mabtech) followed by streptavidin-ALP (Mabtech) and 
BCIP/NBT substrate. IFNγ spots were counted using a CTL ImmunoSpot S6 micro-
analyzer (Cellular Technology). 
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Supplementary Figure 1. (A) OS curves for LYN in NSCLC patients from the TCGA 
database. Expression was stratified by the median and the Log-rank test was used for 
the statistical analysis. (B-C) Quantification of FOXP3+CD4+ (Treg) cells in LUSC 
specimens from University Clinic of Navarra. The percentage of Tregs in YES1 high 
tumors (upper quartile) was compared to the rest of samples (B) or to the lower quartile 
(C). (D-E) Percentage of CD4+ (D) and CD8+ (E) cells in YES1 high or YES1 low 
NSCLC specimens from the University Clinic of Navarra. (F) Relative abundance of 
Treg cells in LUSC specimens from the TCGA database analyzed with CIBERSORT. 
(G) Individual follow-up of tumor growth of 393P cells injected in athymic nude mice. 
(H) Individual follow-up of the tumor volume in the 393P model shown in Figure 3A. 
(I) Individual follow-up of the tumor volume in the UN680 model in vivo shown in 
Figure 3F.  
Supplementary Figure 2. (A) Western blotting of phospho SFKs (pSFKs), phospho 
STAT3 (Y705) (pSTAT3), STAT3, phospho-ERK1/2 (pERK 1/2), ERK1/2, phospho-
AKT (ser473) (pAKT), AKT and β-actin performed with protein extracts coming from a 
subcutaneous in vivo experiment (short-term treatment) with 393P cells. (B) 
Densitometric quantification of the protein levels corresponding to pSFKs after 
normalization with β actin expression. (C) Western blotting for YES1 in the 393P cell 
line infected with a shRNA control (sh-scramble) or a shRNA targeting YES1 (sh-
YES1). (D) In vivo growth of 393P tumors after injection of transduced cells (either sh-
scramble or sh-YES1) into Sv/129 mice, with or without anti-PD-1 treatment (100 µg, 
days 6, 9 and 12). 
Supplementary Figure 3.  (A) Evolution of subcutaneous growth of 393P tumors 
undergoing single or combined treatments with dasatinib (30 mg/kg, daily) and/or anti-
PD-1 (100 µg, days 4, 7 and 10). At day 14 of the experiment, animals (n=8 per group) 
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were sacrificed and tumors harvested for flow cytometry analysis of the tumor-immune 
infiltrate. (B-F) Flow cytometry showing percentage of tumor-infiltrating macrophages 
(F4/80+), B cells (CD19+), NK cells (NK1.1+), M-MDSCs (Ly6Chigh Ly6Glow/-) and 
PMN-MDSC (Ly6Ghigh Ly6C low) cells. All data were referred to the percentage of 
CD45+ cells. (G-I) PD-L1 median fluorescence intensity (MFI) in M-MDSC, PMN-
MDSC and macrophages. (J-K) PD-L1 MFI in 393P (left) and UN680 (right) cells after 
addition of dasatinib (5µM or 10µM for 72h) and IFNɣ (500 U/mL) in vitro. 
Supplementary Figure 4. (A-B) Flow cytometry gating strategy for tumor-infiltrating 
B cells, NK cells, CD8 T cells, CD4 T cells, Tregs and MDSCs. After excluding 
doublets, leukocytes were selected using leukocyte common antigen CD45. Within 
CD45-positive cells, B cells, NK cells, CD8 T cells, CD4 T cells and CD11b+ cells 
were delimited as the CD19+, NK1.1+, CD8+  CD4+ cells and CD11b+ cells, 
respectively. Tregs were gated from CD4 T cells as the double positive population for 
CD25 and FOXP3 markers. M-MDSCs and PMN-MDSCs were gated from CD11b+ 
cells as Ly6Chigh Ly6Glow/- and Ly6Ghigh Ly6Clow, respectively. 
Supplementary Figure 5. (A-D) Multiplex immunofluorescence (mIF) analysis of 
CD4+, macrophages (F4/80+), CD8+ and CD31+ cells in 393P tumors (n=8). (E) 
Representative mIF images to show CD8+, CD4+, F4/80+ and CD31+ cells (upper 
panel) or all markers (lower panel) in one of the tumors. (F) Tumor growth of 393P 
cells subcutaneously injected in Sv/129 mice for studying circulating CD4+, CD8+ and 
Tregs by flow cytometry. Data are expressed as mean ± SEM and were analyzed with a 
one-way ANOVA test followed by a post-hoc Bonferroni test.  **p<0.01; ***p<0.001. 
Supplementary Figure 6. (A) Flow cytometry analysis of the CD8+ T cell population 
after treatment with anti-CD8α depleting antibody (100 µg, days 2, 6, 10 and 14) in 
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393P tumors.  (B-F) Densitometric quantification of the protein levels corresponding to 
pLCK (B), pSTAT5 (C), pSMAD3 (D), STAT5 (E) and SMAD3 (F). 
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